Funder
Kræftens Bekæmpelse
Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat
Dansk Kræftforsknings Fond
Region Sjællands Sundhedsvidenskabelige Forskningsfond
Dansk Brystkirurgisk Selskabs legat
Helsefonden
Interne Forskningsmidler, Herlev and Gentofte Hospital, Copenhagen University Hospital
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. The Danish Breast Cancer Group (2020). Kvalitetsindikatorrapport for Brystkræft [Internet]. Available from: https://dbcg.dk/images/PDF/Rapporter/DBCG_årsrapport_2020_Publiceret_FINAL.pdf
2. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700–5706
3. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P et al (2019) Breast cancer. Nat Rev Dis Prim 5(1):66
4. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283
5. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献